ANN ARBOR, Mich.–(BUSINESS WIRE)—- $NDRA #MASLD–ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the third quarter ended September 30, 2026, and provided a business update. Business Update During the third quarter of 2026, ENDRA continued to manage its operating costs while continue to develop its third-generation ultrasound product. At th

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.